

Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1-36. (canceled)

37. (currently amended) A composition of matter comprising as an admixture at least one compound selected from group (i) and ~~at least one compound selected from group (ii)~~ oxybutynin,

wherein group (i) consists of:

~~Group a) consisting of:~~


~~—— tramadol, O-demethyltramadol or O-demethyl-N-mono-demethyl-tramadol,~~

~~Group b) consisting of:~~

- ~~• codeine~~
- ~~• dextropropoxyphene~~
- ~~• dihydrocodeine~~
- ~~• diphenoxylate~~
- ~~• ethylmorphine~~
- ~~• meptazinol~~
- ~~• nalbuphine~~
- ~~• pethidine~~
- ~~• tilidine~~
- ~~• tramadol~~
- ~~• viminol~~
- ~~• butorphanol~~
- ~~• dextromoramide~~
- ~~• dezocine~~
- ~~• diacetylmorphine~~

- hydrocodone
- hydromorphone
- ketobemidone
- levomethadone
- levomethadyl acetate (1- α -acetylmethadol)
- levorphanol
- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanyl
- sufentanil

Group c) consisting of: 1-phenyl-3-dimethylamino-propane compounds
corresponding to formula I



wherein

X is OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl,
branched or unbranched, saturated or unsaturated,
unsubstituted or mono- or polysubstituted,

R¹ is chosen from C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R² and R³ in each case independently of one another are chosen from H or C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, or

R² and R³ together form a saturated C₄₋₇-cycloalkyl radical, unsubstituted or mono- or polysubstituted,


R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

where R¹⁷ and R¹⁸ in each case independently of one another are chosen from H; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

R⁹ and R¹⁰ or R¹⁰ and R¹¹ together form an OCH₂O, OCH₂CH₂O, OCH=CH, CH=CHO, CH=C(CH₃)O, OC(CH₃)=CH, (CH₂)₄ or OCH=CHO ring,

~~Group d) consisting of substituted 6-dimethylaminomethyl-1-phenyleyclohexane compounds corresponding to formula II~~



II

wherein

~~X is OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,~~

~~R¹ is C₁₋₄-alkyl, benzyl, CF₃, OH, OCH₂-C₆H₅, O-C₁₋₄-alkyl, Cl or F and~~


~~R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃, SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;~~

~~where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl~~

~~groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R^{17} and R^{18} in each case independently of one another are chosen from the group consisting of H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or~~

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group e) consisting of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

~~X is OH, F, Cl, H or $OC(O)R^7$, where R^7 is chosen from C_{1-3} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and~~

~~R^9 to R^{13} in each case independently of one another are chosen from H, F, Cl, Br, I, CH_2F , CHF_2 , CF_3 , OH, SH, OR^{14} , OCF_3 , SR^{14} , $NR^{17}R^{18}$, $SOCH_3$, $SOCF_3$, SO_2CH_3 , SO_2CF_3 , CN, $COOR^{14}$, NO_2 , $CONR^{17}R^{18}$, C_{1-6} -alkyl, branched or unbranched, saturated or~~

~~unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;~~

~~where R¹⁴ is chosen from the group consisting of C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R¹⁷ and R¹⁸ in each case independently of one another are chosen from H; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or~~

~~R⁹ and R¹⁰ or R¹⁰ and R¹¹ together form an OCH₂O, OCH₂CH₂O, OCH=CH, CH=CHO, CH=C(CH₃)O, OC(CH₃)=CH, (CH₂)₄ or OCH=CHO ring,~~

~~with the proviso that if R⁹, R¹¹ and R¹³ correspond to H and one of R¹⁰ or R¹² corresponds to H and the other corresponds to OCH₃, X may not be OH, and~~

~~wherein group (ii) consists of an anti-muscarine agent selected from the group consisting of atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and α,α -diphenylacetic acid 4-(N-methylpiperidyl) ester, duloxetine, imipramine and desmopressin, or a salt of any of the foregoing with a physiologically tolerated acid.~~

38. (withdrawn-currently amended) The composition of matter of claim 37, wherein one or more of

said at least one compound selected from group (i) and

~~said at least one compound selected from group (ii)~~ oxybutynin

is present in the form of a free base.

39. (currently amended) The composition of matter of claim 37, wherein one or more of

said at least one compound selected from group (i) and

~~said at least one compound selected from group (ii)~~ oxybutynin

is present in the form of a pure enantiomer or pure diastereoisomer.

40. (withdrawn-currently amended) The composition of matter of claim 37, wherein one or more of

said at least one compound selected from group (i) and

~~said at least one compound selected from group (ii)~~ oxybutynin

is present in the form of a mixture of stereoisomers.

41. (withdrawn-currently amended) The composition of matter of claim 40, wherein one or more of

said at least one compound selected from group (i) and

~~said at least one compound selected from group (ii)~~ oxybutynin

is present in the form of a racemic mixture.

42-47. (canceled)

48. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ and H,

R¹ is chosen from C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched;

R² and R³ independently of one another are chosen from the group consisting of H, and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; or

R² and R³ together form a C₅₋₆-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R⁹ to R¹³ are independently chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃ and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from the group consisting of Cl, F, OH, CF₂H, CF₃, OR¹⁴ and SR¹⁴, or

if R⁹ and R¹³ correspond to H, and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F, or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from the group consisting of OH, OC₂H₅ and OC₃H₇.

49. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein X is chosen from the group consisting of OH, F, OC(O)CH₃ and H.

50. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R¹ is CH₃, C₂H₅, C₄H₉ or t-butyl.


51. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^2 and R^3 independently of one another are chosen from the group consisting of H, CH_3 , C_2H_5 , i-propyl and t-butyl.

52. (withdrawn-previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^2 and R^3 together form a C_{5-6} -cycloalkyl radical which is saturated and unsubstituted.

53. (withdrawn-previously presented) The composition of matter of claim 52, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^2 and R^3 together form a cyclohexyl group.

54. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^9 to R^{13} independently of one another are chosen from the group consisting of H, Cl, F, OH, CF_2H , CF_3 , OCH_3 and SCH_3 ; with the proviso that 3 or 4 of the radicals R^9 to R^{13} must correspond to H.

55. (previously presented) The composition of matter of claim 48, wherein compounds corresponding to formula I where $R^3 = H$ are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

56. (previously presented) The composition of matter of claim 48, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

57. (previously presented) The composition of matter of claim 48, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,
- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,

- (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
 - (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
 - (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
 - (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
 - (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, and
 - (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,
- and hydrochloride salts of the foregoing.

58-72. (canceled)

73. (previously presented) A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim 37 and at least one pharmaceutically suitable additive or auxiliary substance.